Genmab is an international biotechnology company that creates, develops, and commercializes antibody therapeutics for the treatment of cancer and other serious diseases. The company's pipeline includes bispecific T-cell engagers, immune checkpoint modulators, effector function enhanced antibodies, and antibody-drug conjugates (ADCs). Key commercial products include epcoritamab (marketed as EPKINLY and TEPKINLY) in collaboration with AbbVie, and tisotumab vedotin (marketed as Tivdak) co-developed with Pfizer. Genmab also holds royalty interests in partner-developed medicines such as daratumumab (DARZALEX), amivantamab (RYBREVANT), teclistamab (TECVAYLI), talquetamab (TALVEY), ofatumumab (Kesimpta), and teprotumumab (TEPEZZA). The company utilizes proprietary technology platforms including DuoBody, HexaBody, DuoHexaBody, HexElect, and ADC platforms acquired from ProfoundBio. Genmab serves markets in the US, Europe, Japan, and other regions, focusing on indications such as multiple myeloma, cervical cancer, ovarian cancer, and non-small cell lung cancer. Incorporated in 1998, the company operates through strategic collaborations and selective acquisitions, including the 2025 acquisition of Merus N.V.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage genmab.com
Sector Healthcare IR page genmab.com/investor-relations
Tags
antibody therapeutics, bispecific antibodies, antibody-drug conjugates, oncology, multiple myeloma, cervical cancer, ovarian cancer, non-small cell lung cancer, immune checkpoint modulators, t-cell engagers, EPKINLY, TEPKINLY, Tivdak, DARZALEX, DARZALEX FASPRO, DARZALEX SC, RYBREVANT, RYBREVANT FASPRO, TECVAYLI, TALVEY, Kesimpta, TEPEZZA, BIZENGRI, DuoBody, HexaBody, DuoHexaBody, HexElect, ProfoundBio, Merus, Partner Therapeutics, epcoritamab, Rina-S, petosemtamab, tisotumab vedotin, daratumumab, amivantamab, teclistamab, talquetamab, ofatumumab, teprotumumab, Zenocutuumab-zbco
Press page —

Metrics

Valuation  
Market cap DKK 22.917B
Market cap (USD) $ 3.363B
P/E 28.20
PEG —
P/BV 3.85
P/S 5.55
P/OCF 25.72
P/FCF 26.37
Dividend yield —
Turnover / mcap —
Returns  
ROE 24.3%
ROI 8.9%
ROIC 7.9%
Profit margin 25.9%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity 81.3%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 73
Quality score 18.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2019 FY 2018
Revenue 3.72B 799.491M 471.844M
Net profit 963M 322.717M 229.605M
Free cash flow 1.149B 185.793M 147.091M

Figure FY 2025 FY 2019 FY 2018
Share price 30.8 22.33 16.42
Price performance 12m 0.48 0.36 -0.8

Filed figures

Figure Dec 2017 Dec 2018 Dec 2019 Dec 2023 Dec 2024 Dec 2025
Income detail
Research and development expense (DKK) 874M 1.43B 2.39B 1.11B 1.41B 1.61B
Reported Mar 30, 2020 Mar 30, 2020 Mar 30, 2020 Feb 17, 2026 Feb 17, 2026 Feb 17, 2026

Operating KPIs — quarters

KPI Dec 24 Mar 25 Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 Sep 26
Properties 128 126 125 121 127 — — 185
↳ YoY growth -0.8% +52.9%
Employees — 2,669 2,639 2,681 — 3,088 3,119 3,244
↳ YoY growth +5.3% +15.7% +18.2% +21.0%
Reported May 8, 2025 May 8, 2025 Aug 6, 2026 Nov 5, 2026 Nov 5, 2026 May 7, 2026 Aug 6, 2026 Nov 5, 2026

Operating KPIs — years

KPI Dec 2024 Dec 2025
Properties 128 127
↳ YoY growth -0.8%
Reported May 8, 2025 Nov 5, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Company Announcement

COPENHAGEN, Denmark; November 18, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 4,993 restricted stock units and 4,607 warrants to employees of the Company and the Company's subsidiaries.

Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 3,496.

The restricted stock units will vest on the first banking day of the month following a period of three years from the date of grant. Furthermore, the restricted stock units are subject to vesting conditions set out in the restricted stock unit program adopted by the Board of Directors. Information concerning Genmab’s restricted stock unit program can be found on www.genmab.com under Investors > Governance > Compensation > Restricted Stock Units.

The exercise price for each warrant is DKK 3,496. Each warrant is awarded cost-free and entitles the owner to subscribe one share of nominally DKK 1 subject to payment of the exercise price.

Genmab — Announcement (Form 6-K) Bull 0 Bear 0 Routine

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Genmab A/S Tel: +45 7020 2728 Company Announcement no. 47 Carl Jacobsens Vej 30 www.genmab.com Page 1/15 2500 Valby, Denmark CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 Company Announcement COPENHAGEN, Denmark; November 10, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons. Please find below a statement of such trading in shares issued by Genmab A/S. The sale of shares will take Jan van de Winkel’s personal holding of shares in Genmab A/S from 668,024 shares to 646,024 shares. 1.

Company Announcement

COPENHAGEN, Denmark; November 11, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.

The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons.

Please find below a statement of such trading in shares issued by Genmab A/S

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Bradley Bailey

2.

Reason for the notification

a)

Position/status

Executive Vice President, Chief Commercial Officer

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Genmab A/S

b)

LEI-code

529900MTJPDPE4MHJ122

4.

Prompts

Genmab (ticker GMAB), listed in United States.

Company History

Date Change Detail
Jun 30, 2025 Reporting currency Its US reports are in USD instead of DKK from this period. Earlier figures are shown in USD, converted at each period end's exchange rate.
— Different company 529900MTJPDPE4MHJ122 (CIK 529900MTJPDPE4MHJ122) is a different company that has used this ticker. Its filings are not shown here.

ETFs Holding Genmab

ETF Weight in ETF Shares Market value As of
AADR 3.65% 22,924 $ 1.191M Nov 17, 2026
CANC 2.88% 183,357 $ 6.08M Aug 31, 2026
BMED 2.60% 7,231 $ 372.903K Nov 16, 2026
DSTX 0.85% 1,454 $ 399.194K Jun 30, 2026
TDI 0.69% 9,051 $ 2.484M Jun 30, 2026
FTQI 0.38% 70,541 $ 3.638M Nov 16, 2026
LCTD 0.38% 2,324 $ 1.208M Nov 16, 2026
FENI 0.33% 122,836 $ 33.706M Jun 30, 2026
DFIV 0.30% 139,399 $ 68.24M Nov 12, 2026
DTAN 0.23% 98 $ 50.542K Nov 17, 2026
DFSI 0.21% 4,665 $ 2.438M Nov 12, 2026
ENHI 0.16% 66 $ 34.293K Nov 16, 2026
IDYN 0.16% 350 $ 181.855K Nov 16, 2026
AVDE 0.14% 517,449 $ 26.685M Nov 16, 2026
DFAI 0.11% 52,252 $ 20.111M Nov 12, 2026
DFAX 0.10% 23,741 $ 12.406M Nov 12, 2026
APIE 0.09% 32,968 $ 1.093M Aug 31, 2026
AVSD 0.09% 6,750 $ 348.098K Nov 16, 2026
DFIC 0.09% 27,816 $ 13.688M Nov 12, 2026
FLSP 0.09% 2,994 $ 821.999K Jun 30, 2026
NTSI 0.08% 1,461 $ 401.116K Jun 30, 2026
JSTC 0.06% 3,497 $ 180.34K Nov 17, 2026
AVIV 0.05% 18,799 $ 969.464K Nov 16, 2026
RGLO 0.03% 414 $ 113.6K Jun 30, 2026
DXIV 0.01% 57 $ 29.786K Nov 12, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
GMAB canonical Common share — US nasdaq 35.68 USD 2026-09-30
GMAB Common share — DK nordic — —